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Abstract
Adrenomedullin (AM) is a potent vasodilator that plays a major role in the cardiovascular response during the progression
of sepsis. Although pulmonary clearance of AM (i.e., the primary site of AM clearance) is reduced during the late,
hypodynamic stage of sepsis, the role of AM receptors under such conditions remains unclear. This study was carried out to
test the hypothesis that saturation of AM receptors is responsible for the decreased clearance of AM in the lungs during
sepsis. Polymicrobial sepsis was induced in male adult rats by cecal ligation and puncture (CLP). At 20 h after CLP (i.e., the
late phase), 125I-labeled rat AM was administered through the jugular vein, both with (+) and without (3) pre-injection of the
human AM fragment AM22ÿ52 (an AM receptor antagonist). Pulmonary tissue samples were harvested after 30 min and the
radioactivity was determined. In addition, lung levels of AM were determined at 5 and 20 h after CLP by radioimmunoassay.
Alterations in gene expression of the recently identified AM receptor subunits calcitonin receptor-like receptor (CRLR) and
receptor activity modifying protein-2 and -3 (RAMP-2 and -3) were assessed in the lungs by reverse transcription^polymerase
chain reaction (RT^PCR) at 5 and 20 h after CLP. The results indicate that there was a significant decrease in pulmonary
[125I]AM clearance at 20 h in 3AM22ÿ52 CLP animals. Lung clearance in +AM22ÿ52 sham animals was significantly lower
than in 3AM22ÿ52 sham animals and was not statistically different from the 3AM22ÿ52 CLP group. There was no statistical
difference between +AM22ÿ52 and 3AM22ÿ52 CLP groups. However, there was a significant increase in lung AM levels at 20
but not 5 h after CLP. In addition, RAMP-3 expression was significantly upregulated at 5 but not 20 h after CLP. There were
no alterations in the expression of CRLR or RAMP-2 at either time point. These results suggest that pulmonary AM
receptors become saturated as more AM enters the bloodstream, thereby reducing the ability of the lungs to clear this peptide
during late sepsis. Early upregulation of RAMP-3 may be a compensatory mechanism to help clear the upregulated AM from
the bloodstream. The lack of upregulation of RAMP-3 during late sepsis could also contribute to the decreased clearance
observed during this phase. ß 2002 Elsevier Science B.V. All rights reserved.
Keywords: Adrenomedullin receptor antagonist; Calcitonin receptor-like receptor; Receptor activity modifying protein; Cecal ligation
and puncture; Vasoactive peptide
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1. Introduction
Adrenomedullin (AM), a recently reported potent
vasodilatory peptide, has been shown to be upregu-
lated under various adverse circulatory conditions,
including heart failure [1], renal failure [2], ischemia
and reperfusion [3], and endotoxic shock [4,5]. Pre-
vious studies from our laboratory using the cecal
ligation and puncture (CLP) model of polymicrobial
sepsis have shown that plasma levels of AM increase
as early as 2 h after the onset of sepsis and remain
elevated during the late, hypodynamic phase [6]. In
addition, AM gene expression is upregulated in the
small intestine, left ventricle, and aorta [6]. More-
over, the small intestine has been identi¢ed as the
major source of AM release during sepsis [7]. With
regard to the clearance of this peptide, it has been
demonstrated that the lungs are the primary site of
AM clearance [8^11]. We previously reported that
pulmonary clearance of [125I]AM is reduced during
the late, hypodynamic stage of polymicrobial sepsis,
which could contribute to the elevated plasma levels
of AM observed during this stage [8]. However, it
remains unknown whether the reduced pulmonary
clearance of AM observed during the late stage of
sepsis is due to saturation of AM receptors in the
lungs. It could be possible that during the progres-
sion of sepsis, as more AM accumulates in the blood-
stream, the clearance mechanism (i.e., AM receptors)
in the lungs becomes saturated. In this study, we
hypothesized that blockade of AM receptors with
an AM antagonist, AM22ÿ52; would signi¢cantly re-
duce the clearance capacity of the lungs in sham
animals but would be ine¡ective in reducing AM
clearance during late sepsis because of prior satura-
tion by endogenous AM. The aim of this study,
therefore, was to investigate the role of AM receptors
in the clearance of this peptide during sepsis. We also
tested the hypothesis that alterations in AM recep-
tors could be responsible for the inability of the lungs
to clear increasing amounts of AM from the blood-
stream during the progression of sepsis. Reverse
transcription^polymerase chain reaction (RT^PCR)
was performed to determine alterations in gene ex-
pression of the newly identi¢ed AM receptor sub-
units: calcitonin receptor-like receptor (CRLR),
and receptor activity modifying protein-2 and -3
(RAMP-2 and -3).
2. Materials and methods
2.1. Animal model of polymicrobial sepsis
Male Sprague^Dawley rats (275^325 g, Charles
River Laboratories, Wilmington, MA) were sub-
jected to polymicrobial sepsis by CLP as previously
described [12]. Brie£y, rats were fasted overnight, but
allowed water ad libitum. After anesthetization with
methoxy£urane inhalation, a 3-cm ventral midline
incision was made, and the cecum was exposed and
ligated with a 3-0 silk ligature just distal to the ileo-
cecal valve. The cecum was then punctured twice
with an 18-gauge needle, squeezed slightly to allow
a small amount of fecal matter to £ow from the
holes, and then returned to the abdominal cavity.
The incision was closed in layers and the animal
received a subcutaneous injection of normal saline
(3 ml/100 g body weight, i.e., £uid resuscitation).
Sham-operated animals were subjected to the same
procedure though the cecum was neither ligated nor
punctured. The experiments described herein were
performed in accordance with the National Institutes
of Health guidelines for the use of experimental ani-
mals. This project was approved by the Institutional
Animal Care and Use Committee of the University
of Alabama at Birmingham.
2.2. Administration of AM receptor antagonist and
radioactive AM
At 20 h after CLP (i.e., the late, hypodynamic
phase of sepsis) [13] or sham operation, the animals
were anesthetized again with methoxy£urane inhala-
tion. A steady state of sedation was maintained with
a subsequent intravenous injection of sodium pento-
barbital (V50 mg/kg body weight). Polyethylene-50
catheters were placed in the right jugular vein and
left femoral artery, and a bolus injection of the AM
receptor antagonist human AM22ÿ52 (Phoenix Phar-
maceuticals, Belmont, CA; 18.67 Wg/kg body weight)
was administered through the jugular cannula. This
dose produced a plasma concentration approxi-
mately 500-fold higher than circulating AM concen-
trations observed during the late stage of sepsis, pre-
sumably saturating all AM receptors. After 10 min,
125I-labeled rat AM (Peninsula Labs, Belmont, CA;
0.67 ng/kg at a speci¢c activity of 2995 Ci/mmol;
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V300 000 cpm/rat) was then administered. The re-
maining radioactivity in the syringe was measured
with a gamma counter (1480 Wizard, Wallac, Gai-
thersburg, MD), and this radioactivity count was
subtracted from the initial, pre-injection count to de-
termine the net injected radioactivity. Thirty minutes
after the administration of [125I]AM, a blood sample
was drawn, the inferior vena cava was cut, and the
animal was perfused with 100 ml of warm, oxygen-
ated normal saline through the femoral arterial can-
nula to remove blood from tissues. Following the
perfusion, the lungs were harvested and weighed,
and the radioactivity (cpm) was measured with the
gamma counter. The pulmonary distribution of
[125I]AM was calculated as the percentage of the total
radioactivity administered per gram of wet tissue.
2.3. Determination of lung AM levels
Lung tissue samples were harvested at 5 and 20 h
after CLP or sham operation, snap-frozen in liquid
nitrogen, and stored at 380‡C until use. The tissue
samples were then homogenized in equal volumes of
supplied Bu¡er A (1% tri£uoroacetic acid in water)
and saline solution, centrifuged at 3000 rpm for 30
min, and the supernatant was frozen at 380‡C until
further use. Lung AM levels were determined by ra-
dioimmunoassay according to the manufacturer’s in-
structions and guidelines (Phoenix Pharmaceuticals,
Mountain View, CA). Brie£y, AM was extracted
from the acidi¢ed tissue homogenates using SEP-col-
umns packed with 200 mg C18 sorbent (Peninsula
Laboratories, Belmont, CA) and eluted with supplied
Bu¡er B (60% acetonitrile in 1% tri£uoroacetic acid).
The eluant was then evaporated overnight in a
centrifugal concentrator (Savant Speed Vac Plus
SC110A, Savant Instruments, Farmingdale, NY), re-
constituted in assay bu¡er, and analyzed according
to the manufacturer’s protocol.
2.4. Determination of AM receptor subunit gene
expression
Gene expression of AM receptor subunits (i.e.,
CRLR, RAMP-2, and RAMP-3) was assessed using
RT^PCR analysis. Lung samples were harvested at 5
and 20 h after CLP or sham-operation, snap-frozen
in liquid nitrogen, and stored at 380‡C until use.
Total RNA was extracted using Tri-reagent (Molec-
ular Research Center, Cincinnati, OH) and 4 Wg of
RNA was reverse transcribed as previously described
by us [6]. The resulting cDNAs were ampli¢ed by




CGGT-3P ; antisense, 5P-ACATCCTCTGGGGGAT-
CGGAGA-3P), and RAMP-3 (sense, 5P-ACCTGT-
CGGAGTTCATCGTG-3P ; antisense, 5P-AC-TTC-
ATCCGGGGGGTCTTC-3P) [14]. Rat glyceralde-
hyde 3-phosphate dehydrogenase (G3PDH) served
as a housekeeping gene (Clontech, Palo Alto, CA).
PCR cycling proceeded as follows: 25 cycles of 94‡C
for 30 s, 60‡C for 30 s, and 72‡C for 90 s. Following
the RT^PCR procedure, the PCR ampli¢cation
products were electrophoresed using a 1.6% agarose
gel containing 0.22 mg/ml ethidium bromide. The gel
was then photographed using Polaroid ¢lm. Optical
density of target and housekeeping gene bands were
determined by ChemiImager 5500 software. Target/
G3PDH band density ratios were then calculated.
2.5. Statistical analysis
Results are presented as mean þ S.E.M. One-way
analysis of variance (ANOVA) and Tukey’s test were
used for statistical analysis, and the di¡erences were
considered signi¢cant at P90.05.
3. Results
3.1. Pulmonary [125I]AM distribution after AM
receptor blockade
Since we have previously demonstrated that
[125I]AM distribution was not altered at 5 h after
CLP [7], we only determined e¡ects of AM receptor
antagonism on pulmonary [125I]AM distribution at
20 h after CLP in the present study. As shown in
Fig. 1, despite a 27% decrease in lung radioactivity
at 20 h after CLP in animals with pre-injection of
AM22ÿ52 as compared to sham-operated animals, this
di¡erence was not signi¢cant. This lies in contrast to
the results reported previously [8], which showed sig-
ni¢cantly reduced pulmonary clearance at 20 h after
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CLP without administration of AM22ÿ52 (20.46 þ
0.75% total radioactivity/g tissue in sham group ver-
sus 11.99 þ 2.00% total radioactivity/g tissue in CLP
group) (Fig. 1). It should be noted that the wet
weight of lungs was 1.18 þ 0.07 g (SD) with body
weight of 314 þ 12 g in randomly selected rats
(n = 10). Thus, the distribution of [125I]AM to the
pulmonary tissue was approximately 24% of total
radioactivity administered in sham-operated animals.
In addition, there was a signi¢cant decrease in lung
radioactivity in the sham group injected with
AM22ÿ52 as compared to the sham group without
pre-injection of AM22ÿ52. In contrast, there was no
statistical di¡erence in lung levels of radioactivity at
20 h after CLP with and without AM22ÿ52 pre-infu-
sion (Ps 0.05, Fig. 1). The distribution of [125I]AM
in blood was very low as compared to the pulmonary
tissue. The level was 0.445 þ 0.019 and 0.462 þ
0.038% total radioactivity/ml in sham and CLP 5 h
animals, respectively. At 20 h after CLP, it increased
to 0.638 þ 0.011% total radioactivity/ml (P6 0.05 vs.
sham). Please note that these results are comparable
to our previously reported data without administra-
tion of AM22ÿ52 [8].
3.2. Alterations in lung levels of AM
Alterations in lung AM levels are summarized in
Fig. 2. At 5 h after CLP, there were no signi¢cant
increases in lung AM levels. At 20 h after CLP, how-
ever, septic animals showed approximately a three-
fold increase as compared to sham-operated animals
(P6 0.05, 111.3 þ 11.5 versus 27.7 þ 7.9 ng/g wet tis-
sue in sham animals).
3.3. Alterations in AM receptor subunit gene
expression
The results in Fig. 3 indicate that the RT^PCR
products (181 bp) of the RAMP-3 gene increased
Fig. 3. Representative gel of gene expression of RAMP-3 (181
bp) in the lungs as well as the housekeeping gene G3PDH (983
bp). Lane 1, X174/Hae III size markers; lane 2, RAMP-3 at 5 h
in sham animals; lane 3, RAMP-3 at 5 h in CLP animals; lane
4, RAMP-3 at 20 h in shams; lane 5, RAMP-3 at 20 h in
CLPs. Lanes 6^9 are the corresponding G3PDH bands.
Fig. 2. Changes in pulmonary AM levels at 5 and 20 h after
CLP or sham operation. The data are presented as means
þ S.E.M. (n = 6^7/group) and compared by one-way ANOVA
and Tukey’s test. *P6 0.05 versus the respective sham-operated
animals.
Fig. 1. Changes in pulmonary [125I]AM clearance at 20 h after
CLP, with (+) or without (3) pre-injection of the AM receptor
antagonist AM22ÿ52. The data are presented as means þ S.E.M.
(n = 6^7/group) and compared by one-way ANOVA and Tu-
key’s test. *P6 0.05 versus the respective sham operated ani-
mals; #P6 0.05 versus the respective 3AM22ÿ52 group. Lung
clearance of [125I]AM following pre-injection of AM22ÿ52 was
not statistically di¡erent between the sham and CLP groups, in-
dicating that CLP does not further decrease AM uptake beyond
the e¡ect of AM22ÿ52 injection alone. Please note that pulmo-
nary distribution of [125I]AM in animals without AM22ÿ52 pre-
injection has been previously published [8].
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in the lungs at 5 h after the onset of sepsis (lane 3) as
compared to sham-operated animals (lane 2). In con-
trast, there were no alterations in RAMP-3 gene ex-
pression at 20 h after CLP (lanes 4 and 5). Fig. 3
indicates that expression of the housekeeping gene
G3PDH (983 bp) was similar in both sham and
CLP groups at both time points (lanes 6^9), indicat-
ing that similar levels of reverse transcription were
achieved. The target/G3PDH band ratio results indi-
cate that the RAMP-3 ratio increased signi¢cantly at
5 but not 20 h after the onset of sepsis as compared
to the respective sham-operated group (Fig. 4). Un-
like RAMP-3, there were no signi¢cant changes in
CRLR or RAMP-2 gene expression at either time
point (Figs. 5 and 6).
4. Discussion
After it was ¢rst isolated from human pheochro-
mocytoma in 1993 by Kitamura et al. [15], AM was
quickly established as an important mediator in sev-
eral physiological as well as pathophysiological pro-
cesses. In addition to its well-known vasodilatory
e¡ects, AM is known to be involved in the regulation
of renal function [16], bronchodilation [17], inhibi-
tion of hormone secretion (including insulin, adreno-
corticotropic hormone, aldosterone) [18^20], neuro-
transmission [21], and mitogenic activity [22,23]. Our
recent studies have focused on the transition from
the early, hyperdynamic stage of sepsis to the late,
hypodynamic phase, and it has become increasingly
clear that AM is an important mediator in this pro-
cess [24]. We have shown that plasma levels of AM
are elevated as early as 2 h after the onset of sepsis,
with gene expression upregulated in the small intes-
tine, heart, and aorta [6]. If AM is administered in
normal rats, they exhibit a typical hyperdynamic re-
Fig. 5. Changes in pulmonary CRLR gene expression at 5 and
20 h after (CLP) or sham operation. The data (expressed as ra-
tio of target gene RAMP-3 and housekeeping gene G3PDH)
are presented as means þ S.E.M. (n = 3^4/group) and compared
by one-way ANOVA. There was no statistical di¡erence be-
tween CLP and respective sham-operated animals.
Fig. 6. Changes in pulmonary RAMP-2 gene expression at 5
and 20 h after (CLP) or sham operation. The data (expressed
as ratio of target gene RAMP-3 and housekeeping gene
G3PDH) are presented as means þ S.E.M. (n = 3^4/group) and
compared by one-way ANOVA. There was no statistical di¡er-
ence between CLP and respective sham-operated animals.
Fig. 4. Changes in pulmonary RAMP-3 gene expression at 5
and 20 h after (CLP) or sham operation. The data (expressed
as ratio of target gene RAMP-3 and housekeeping gene
G3PDH) are presented as means þ S.E.M. (n = 4^6/group) and
compared by one-way ANOVA and Tukey’s test. *P6 0.05 ver-
sus the respective sham-operated animals.
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sponse, i.e., increased cardiac output, stroke volume
and microvascular blood £ow and decreased periph-
eral vascular resistance. Moreover, anti-AM antibod-
ies administered shortly after CLP completely pre-
vented the hyperdynamic response associated with
early sepsis [25]. Although it has been suggested
that AM is responsible for producing the severe
drop in blood pressure associated with endotoxic
shock [26], we have shown that the transition to
the hypodynamic state appears to be the result of
decreased vascular responsiveness to AM [27]. With
regard to the clearance of this peptide, we have pre-
viously demonstrated that pulmonary clearance of
AM is reduced during the late stage of sepsis [8].
Although saturating the clearance mechanism with
large amounts of unlabeled AM produced similar
results in normal rats, the role that receptors play
in this phenomenon remains unknown. The present
study was therefore conducted to elucidate their role
by using the speci¢c AM receptor antagonist
AM22ÿ52 to determine how much clearance is recep-
tor mediated and how much is the result of non-
speci¢c metabolism. Although no synthetic AM re-
ceptor antagonist is currently available, the human
AM fragment AM22ÿ52 was ¢rst shown to act as a
rat AM receptor antagonist by Eguchi et al., and it
has been widely used to study ligand^receptor inter-
actions of AM [28^30].
Our results indicate that blockade of AM receptors
with AM22ÿ52 signi¢cantly reduces the ability of the
lungs to clear [125I]AM in sham animals, as com-
pared to the sham animals in our original study [8].
In that study, lung clearance in 20 h sham animals
was 20.46% total radioactivity/g tissue, compared to
9.50% total radioactivity/g tissue in 20 h sham ani-
mals pre-injected with AM22ÿ52. Moreover, this value
was not statistically di¡erent from the lung clearance
of 20 h CLP animals in the original study (11.99%
total radioactivity/g tissue). In contrast with the
sham groups, there was no signi¢cant di¡erence in
lung clearance between CLP groups in the two stud-
ies. In addition, while there was no signi¢cant in-
crease in lung levels of AM at 5 h after CLP, there
was a three-fold increase at 20 h after CLP as com-
pared to sham-operated animals, con¢rming the ¢nd-
ing that lung tissue is the primary site of AM clear-
ance. This would suggest that since the receptors are
already saturated with the endogenous AM produced
during the progression of sepsis, the antagonist has
no e¡ect on pulmonary AM clearance, and [125I]AM
is cleared non-speci¢cally at levels similar to those
seen in CLP rats without AM22ÿ52 pretreatment. It
appears that the lungs can clear AM from the blood-
stream in two ways. The ¢rst is mediated by AM-
speci¢c receptors and accounts for about half of the
clearance capacity (as evidenced by the s 50% drop
in radioactivity after administration of AM22ÿ52 in
sham animals) and the other is a non-speci¢c-,
non-receptor-mediated mechanism.
Nishikimi et al. have postulated that lung AM
clearance is pronounced because this peptide prefer-
entially regulates pulmonary vascular tone: AM
more e¡ectively dilates pulmonary vessels when com-
pared to systemic vessels [31]. Little is known, how-
ever, about what cell populations in the lungs are
responsible for the speci¢c and non-speci¢c clearance
of AM. It is possible that endothelial and/or vascular
smooth muscle cells mediate receptor-speci¢c clear-
ance, and macrophages or neutrophils mediate non-
speci¢c clearance. Further in vitro studies would be
helpful in pinpointing the exact cell populations in-
volved in AM clearance in the lungs.
Although there was some early controversy re-
garding the receptor through which AM acts, recent
¢ndings have elucidated the role that receptor activ-
ity modifying proteins (RAMPs) play in determining
the phenotype of the calcitonin receptor-like receptor
(CRLR). In 1998, McLatchie et al. were the ¢rst to
show that the ligand speci¢city of CRLR could be
changed based on the type of RAMP that was coex-
pressed [32]. When RAMP-1 was expressed with
CRLR, a CGRP receptor was created, but when ei-
ther RAMP-2 or RAMP-3 was expressed with
CRLR, an AM receptor was created. RAMPs are
thought to a¡ect CRLR function in three ways:
through receptor tra⁄cking to the cell surface, recep-
tor glycosylation, and receptor^ligand interaction
through either direct or allosteric e¡ects [32^34]. An-
other aim of our study was to determine whether
alterations in gene expression could play a role in
the decrease in [125I]AM clearance during late sepsis.
Our results indicate that RAMP-3 expression is in-
creased in the lungs during the early, hyperdynamic
stage of sepsis but not during the late, hypodynamic
stage. There were no signi¢cant alterations in CRLR
or RAMP-2 at either time point. The ¢ndings that
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the increased RAMP-3 gene expression in early sep-
sis is not associated with signi¢cant changes in pul-
monary AM clearance and that the absence of
RAMP-3 expression changes in late sepsis is associ-
ated with decreased AM clearance may suggest that
there is no direct relationship between AM clearance
and AM receptor gene expression in sepsis. While
further studies are required to determine whether
changes in RAMP-3 gene expression in sepsis are
associated with alterations in binding characteristics
of AM receptors, we believe that upregulation of
RAMP-3 may be part of a compensatory mechanism
to help clear increasing amounts of AM from the
bloodstream during the early stage of sepsis. Without
the increase in AM receptor gene expression under
such conditions, pulmonary AM clearance would
have been reduced. Moreover, the lack of upregula-
tion of RAMP-3 during the later stages of sepsis
could be partly responsible for the decreased ability
of the lungs to clear AM due to the diminished com-
pensatory mechanism. Nonetheless, the ¢ndings that
administration of AM receptor antagonist AM22ÿ52
markedly decreases pulmonary AM clearance in
sham-operated animals (Fig. 1) clearly point out
the important role of AM receptors in AM clearance
by the lungs. Various studies have indicated altera-
tions in CRLR and RAMP expression under adverse
circulatory conditions [35,36]. Ono et al. investigated
the expression of CRLR and RAMP-1^3 in various
organs using a mouse model of endotoxemia [37].
Although they also detected an increase in RAMP-
3 expression in the lungs, they found that CRLR and
RAMP-2 expression decreased, which lies in contrast
to our expression data which showed no changes in
these transcripts. It is possible that the endotoxemia
model elicits a more severe response than the CLP
model of polymicrobial sepsis, which could explain
the di¡erences between our data and the results of
Ono et al. [37].
We have reported that AM levels in the heart and
aorta increased by 93% and 51%, respectively, at 20 h
after CLP [38]. Moreover, intestinal levels of AM
increased by 72% at 20 h after the onset of sepsis [7].
In contrast to those moderate increases in AM levels,
pulmonary AM increased by 302% at 20 h after CLP
in the present study. The ¢nding that the magnitude
of AM increase is much higher in the pulmonary
tissue at 20 h after the onset of sepsis than other
tissues strongly suggests that AM is accumulated in
the lungs during sepsis. Although we have not deter-
mined whether AM mRNA in the lungs is upregu-
lated in sepsis, our previous studies have indicated
that AM gene expression increases in the gut, heart
and aorta in sepsis [6]. While pulmonary AM gene
expression likely may be upregulated during sepsis, a
302% increase in pulmonary levels of AM versus in-
creases of 93%, 51% and 72% increase in the heart,
aorta, and gut, respectively, at 20 h after the onset of
sepsis suggests that the increased pulmonary AM is
due to uptake of AM from the blood in addition to
increased local production. This is further supported
by our previous study that left ventricular adminis-
tration of [125I]AM (i.e., lack of the ¢rst pulmonary
passage) decreased pulmonary [125I]AM distribution
by 46.4% in sham-operated animals [8]. This result,
along with our other ¢ndings, indicates that the
lungs are indeed the major site for the clearance of
AM in sepsis. Despite the fact that plasma and tissue
levels of AM increase signi¢cantly at 20 h after the
onset of sepsis, vascular AM responsiveness de-
creases markedly in the aorta and resistance blood
vessels in the gut at the late stage of sepsis [27].
Although we did not determine pulmonary vascular
responses to AM in our previous study [27], it is
likely that the response of the pulmonary vascular
bed to AM is reduced in late sepsis. In addition,
hemoconcentration occurs during the late stage of
sepsis, indicating that reduction in plasma volume
occurs under such conditions. In view of this, it is
possible that the altered pulmonary vascular tone
and volume may also play a role in producing the
reduction of pulmonary clearance of AM during the
late stage of polymicrobial sepsis.
In summary, our results indicate that blockade of
AM receptors with AM22ÿ52 in sham animals produ-
ces similar levels of pulmonary [125I]AM clearance as
20 h CLP animals without antagonist treatment.
Moreover, lung AM levels are signi¢cantly increased
at 20 but not 5 h after CLP. Gene expression of the
AM receptor subunit RAMP-3 is signi¢cantly in-
creased only during early sepsis, and there were no
alterations in CRLR or RAMP-2 expression at either
time point. These results, taken together, suggest that
the decreased pulmonary clearance of [125I]AM dur-
ing late sepsis is partially due to the saturation of
AM receptors in the lungs by endogenously pro-
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duced AM, which contributes to the elevated plasma
levels of AM observed under these conditions.
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